Co-prescribing naloxone does not increase liability risk

Corey S. Davis, Scott Burris, Leo Beletsky, Ingrid Binswanger

Research output: Contribution to journalEditorial

Abstract

The opioid overdose epidemic claims the lives of tens of thousands of Americans every year. Opioid overdose is reversible by the administration of naloxone, a pure antagonist now available in formulations specifically designed and labeled for layperson use. Despite broad support for layperson access to naloxone from professional organizations, health officials, and clinical experts, qualitative studies suggest that some providers have concerns about legal risks associated with naloxone prescribing, particularly co-prescribing naloxone to pain patients. Such concerns are unfounded. The legal risk associated with prescribing naloxone is no higher than that associated with any other medication and is lower than many. Additionally, laws in a majority of states provide explicit legal protections for providers who prescribe or dispense naloxone, in many cases extending this protection to prescriptions issued to friends, family members, and others. In this large and increasing number of states, the liability risk of prescribing or dispensing naloxone in good faith to a patient at risk of overdose (or, in states where such prescribing is permitted, to an associate of such a patient) is either extremely low or absent entirely. Where a prescriber determines, in his or her clinical judgment, that a patient is at risk of overdose, co-prescribing naloxone is a reasonable and prudent clinical and legal decision. No clinician should fail or refuse to issue such a prescription based on liability concerns.

Original languageEnglish (US)
Pages (from-to)498-500
Number of pages3
JournalSubstance Abuse
Volume37
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Naloxone
Opioid Analgesics
Prescriptions
Pain
Health

Keywords

  • Liability
  • naloxone
  • opioids
  • overdose

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Davis, C. S., Burris, S., Beletsky, L., & Binswanger, I. (2016). Co-prescribing naloxone does not increase liability risk. Substance Abuse, 37(4), 498-500. https://doi.org/10.1080/08897077.2016.1238431

Co-prescribing naloxone does not increase liability risk. / Davis, Corey S.; Burris, Scott; Beletsky, Leo; Binswanger, Ingrid.

In: Substance Abuse, Vol. 37, No. 4, 01.10.2016, p. 498-500.

Research output: Contribution to journalEditorial

Davis, CS, Burris, S, Beletsky, L & Binswanger, I 2016, 'Co-prescribing naloxone does not increase liability risk', Substance Abuse, vol. 37, no. 4, pp. 498-500. https://doi.org/10.1080/08897077.2016.1238431
Davis, Corey S. ; Burris, Scott ; Beletsky, Leo ; Binswanger, Ingrid. / Co-prescribing naloxone does not increase liability risk. In: Substance Abuse. 2016 ; Vol. 37, No. 4. pp. 498-500.
@article{7fa18654ce7f44d5887e0c607afb1aed,
title = "Co-prescribing naloxone does not increase liability risk",
abstract = "The opioid overdose epidemic claims the lives of tens of thousands of Americans every year. Opioid overdose is reversible by the administration of naloxone, a pure antagonist now available in formulations specifically designed and labeled for layperson use. Despite broad support for layperson access to naloxone from professional organizations, health officials, and clinical experts, qualitative studies suggest that some providers have concerns about legal risks associated with naloxone prescribing, particularly co-prescribing naloxone to pain patients. Such concerns are unfounded. The legal risk associated with prescribing naloxone is no higher than that associated with any other medication and is lower than many. Additionally, laws in a majority of states provide explicit legal protections for providers who prescribe or dispense naloxone, in many cases extending this protection to prescriptions issued to friends, family members, and others. In this large and increasing number of states, the liability risk of prescribing or dispensing naloxone in good faith to a patient at risk of overdose (or, in states where such prescribing is permitted, to an associate of such a patient) is either extremely low or absent entirely. Where a prescriber determines, in his or her clinical judgment, that a patient is at risk of overdose, co-prescribing naloxone is a reasonable and prudent clinical and legal decision. No clinician should fail or refuse to issue such a prescription based on liability concerns.",
keywords = "Liability, naloxone, opioids, overdose",
author = "Davis, {Corey S.} and Scott Burris and Leo Beletsky and Ingrid Binswanger",
year = "2016",
month = "10",
day = "1",
doi = "10.1080/08897077.2016.1238431",
language = "English (US)",
volume = "37",
pages = "498--500",
journal = "Substance Abuse",
issn = "0889-7077",
publisher = "Routledge",
number = "4",

}

TY - JOUR

T1 - Co-prescribing naloxone does not increase liability risk

AU - Davis, Corey S.

AU - Burris, Scott

AU - Beletsky, Leo

AU - Binswanger, Ingrid

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The opioid overdose epidemic claims the lives of tens of thousands of Americans every year. Opioid overdose is reversible by the administration of naloxone, a pure antagonist now available in formulations specifically designed and labeled for layperson use. Despite broad support for layperson access to naloxone from professional organizations, health officials, and clinical experts, qualitative studies suggest that some providers have concerns about legal risks associated with naloxone prescribing, particularly co-prescribing naloxone to pain patients. Such concerns are unfounded. The legal risk associated with prescribing naloxone is no higher than that associated with any other medication and is lower than many. Additionally, laws in a majority of states provide explicit legal protections for providers who prescribe or dispense naloxone, in many cases extending this protection to prescriptions issued to friends, family members, and others. In this large and increasing number of states, the liability risk of prescribing or dispensing naloxone in good faith to a patient at risk of overdose (or, in states where such prescribing is permitted, to an associate of such a patient) is either extremely low or absent entirely. Where a prescriber determines, in his or her clinical judgment, that a patient is at risk of overdose, co-prescribing naloxone is a reasonable and prudent clinical and legal decision. No clinician should fail or refuse to issue such a prescription based on liability concerns.

AB - The opioid overdose epidemic claims the lives of tens of thousands of Americans every year. Opioid overdose is reversible by the administration of naloxone, a pure antagonist now available in formulations specifically designed and labeled for layperson use. Despite broad support for layperson access to naloxone from professional organizations, health officials, and clinical experts, qualitative studies suggest that some providers have concerns about legal risks associated with naloxone prescribing, particularly co-prescribing naloxone to pain patients. Such concerns are unfounded. The legal risk associated with prescribing naloxone is no higher than that associated with any other medication and is lower than many. Additionally, laws in a majority of states provide explicit legal protections for providers who prescribe or dispense naloxone, in many cases extending this protection to prescriptions issued to friends, family members, and others. In this large and increasing number of states, the liability risk of prescribing or dispensing naloxone in good faith to a patient at risk of overdose (or, in states where such prescribing is permitted, to an associate of such a patient) is either extremely low or absent entirely. Where a prescriber determines, in his or her clinical judgment, that a patient is at risk of overdose, co-prescribing naloxone is a reasonable and prudent clinical and legal decision. No clinician should fail or refuse to issue such a prescription based on liability concerns.

KW - Liability

KW - naloxone

KW - opioids

KW - overdose

UR - http://www.scopus.com/inward/record.url?scp=84995618154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995618154&partnerID=8YFLogxK

U2 - 10.1080/08897077.2016.1238431

DO - 10.1080/08897077.2016.1238431

M3 - Editorial

VL - 37

SP - 498

EP - 500

JO - Substance Abuse

JF - Substance Abuse

SN - 0889-7077

IS - 4

ER -